Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    World-Pharmacists-Day-Insert
    X

    Find Approved Oncology Drugs in Clinical Development in AUSTRALIA

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Specialised Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              AUSTRALIA Australia

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Natural Products Expo

              Participation Not Confirmed

              Update your events

              New Early Breast Cancer Drug Now Approved in Malaysia

              Contact the Supplier

              Lead Product(s): Neratinib Maleate

              Therapeutic Area: Oncology Product Name: Nerlynx

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 17, 2020

              Details:

              NERLYNX significantly reduce the ongoing risk of recurrence in HER2+ early breast cancer patients with the greatest benefit seen in women who are also HR+and who commence therapy within 12 months of completing trastuzumab-based therapy.

              Cell Therapies

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              AUSTRALIA Australia

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Natural Products Expo

              Participation Not Confirmed

              Update your events

              Novartis announces landmark steps for Kymriah® (tisagenlecleucel): reimbursement for adult DLBCL eligible patients and agreement to manufac...

              Contact the Supplier

              Lead Product(s): Tisagenlecleucel

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 28, 2020

              Details:

              Novartis has entered into an agreement with Cell Therapies to manufacture Kymriah at their production facility within the Peter MacCallum Cancer Centre in Melbourne.

              PharmaCompass__DigitalAd